论文部分内容阅读
AIM:To investigate the effects of vitamin E succinate (VES)on the expression of Fas and PCNA proteins as well as itsclinical significance in human gastric carcinoma,and toexplore the mechanism of VES-induced inhibition of gastriccarcinoma cell growth.METHODS:Immunohistochemical methods were used todetect Fas and PCNA expression both in human gastric cancerSGC-7901 cells treated with VES at different doses and inhuman gastric carcinoma tissues.RESULTS:After the SGC-7901 cells were treated with VESat 5,10,20 mg/L for 48 h,the positive rates of Fas expressionwere 16%,27% and 48%,respectively,significantly increasedcompared to that of control group (P<0.05);while the positiverates of PCNA expression in groups treated with differentdoses of VES were 20%,18% and 7%,respectively,whichwere significantly decreased compared to that of the controlgroup (P<0.05).In human gastric carcinoma tissues,the Faspositive expression rate was 42.4%(25/59),which declinedwith the decrease in the degree of tumor differentiation(P<0.05) and with the existence of lymph node metastasis(P<0.001).While the PCNA positive expression rate was91.5%(54/59),no relationship was observed between PCNAexpression and clinicopathologic parameters.CONCLUSION:VES inhibited the growth of gastric cancercells by inducing Fas expression and inhibiting PCNA expression.It is,therefore,considered that the expression of Fas andPCNA genes,through tumor cell apoptosis and proliferation,respectively,may be useful as a clinical predictive index inthe application of VES to gastric carcinoma therapy,whereas Fas may be of more value than PCNA.
AIM: To investigate the effects of vitamin E succinate (VES) on the expression of Fas and PCNA proteins as well as its clinical significance in human gastric carcinoma, and to explore the mechanism of VES-induced inhibition of gastriccarcinoma cell growth. METHODS: Immunohistochemical methods were used todetect Fas and PCNA expression both in human gastric cancer SGC-7901 cells treated with VES at different doses and inhuman gastric carcinoma tissues .RESULTS: After the SGC-7901 cells were treated with VESat 5, 10, 20 mg / L for 48 h, the positive rates of Fas expressionwere 16%, 27% and 48%, respectively, significantly increasedcompared to that of control group (P <0.05); while the positiverates of PCNA expression in groups treated with differentdoses of VES were 20%, 18% and 7%, respectively, whichwere significantly decreased compared to that of the controlgroup (P <0.05) .In human gastric carcinoma tissues, the Faspositive expression rate was 42.4% (25/59), declined with the decrease in the degree of tumo (P <0.05) and with the existence of lymph node metastasis (P <0.001) .While the PCNA positive expression rate was91.5% (54/59), no relationship was observed between PCNAexpression and clinicopathologic parameters. CONCLUSION: VES inhibited the growth of gastric cancer cells by inducing Fas expression and inhibiting PCNA expression. It is therefore considered that the expression of Fas and PCNA genes, through tumor cell apoptosis and proliferation, respectively, may be useful as a clinical predictive index inthe application of VES To gastric carcinoma therapy, which Fas may be of more value than PCNA.